One in three people will be diagnosed with cancer in their lifetime1

Cancer is the second leading cause of death in the U.S., after heart disease2

In 2022, there were an estimated 1,918,030 new cancer cases diagnosed and 609,360 cancer deaths in the U.S.3

Solid tumors represent approximately 90% of adult human cancers4

Oncology R&D

Immunotherapy is a promising and evolving treatment for cancer that harness the body’s own immune system to target and kill cancer cells. However, not everyone responds to treatment and some immunotherapies are associated with severe side effects.

SalubrisBio is developing JK08 to synergistically widen the therapeutic window for two high-value immunotherapy targets: CTLA-4 and IL15.

NK cells are predictive of response to CTLA-4 antibody therapy
NK cells are predictive of response to CTLA-4 antibody therapy

JK08 builds upon a breadth of clinical studies with CTLA-4 antibodies and recombinant IL-15 molecules demonstrating the therapeutic potential of each molecule individually. The CTLA-4-specific antibody ipilimumab validated CTLA-4 as a target for cancer therapy, but response rates are limited. Clinical sample analysis demonstrated that NK cells are important for ipilimumab responses. Recombinant IL-15 has exhibited potent stimulation of NK cell expansion and activation in pre-clinical and clinical studies. Through the incorporation of a CTLA-4 antibody and IL-15 into a single molecule, JK08 can channel the potent immune stimulation of IL-15 through the CTLA-4 antibody domain towards depletion of T-regulatory cells and targeted reversal of immunosuppression which may contribute to cancer progression.

JK08 is being evaluated in a Phase 1b/2 trial in solid tumors and is actively recruiting patients.

JK08 Design and Rationale

JK08 Design and Rationale